Fragile X Syndrome
Fragile X syndrome is an X-linked trinucleotide repeat expansion disorder in the FMR1 gene, representing the most common inherited cause of intellectual disability and autism spectrum features in children, particularly boys, typically presenting in early childhood with developmental delay, characteristic facial features, and behavioral difficulties.
Fragile X Syndrome (FXS) in Paediatrics
Fragile X syndrome (FXS) is an X-linked genetic disorder caused by a trinucleotide (CGG) repeat expansion in the FMR1 (Fragile X Mental Retardation 1) gene located at chromosome Xq27.3, leading to decreased or absent production of Fragile X Messenger Ribonucleoprotein (FMRP) [1][2][3].
Breaking down the name:
- "Fragile X" → refers to the classical cytogenetic finding of a "fragile site" on the long arm of the X chromosome (Xq27.3), where the chromatin fails to condense properly, making it appear as though the chromosome is "breaking" or "fragile" at that point under specific culture conditions
- "Syndrome" → a constellation of features (intellectual disability, characteristic facial features, behavioural phenotype, connective tissue findings) that occur together
It is the most common inherited cause of intellectual disability and a significant single-gene cause of autism spectrum disorder (ASD) [2].
High Yield – GC Lecture Point
FXS is classified as a single-gene, X-linked disorder – an example of "simple causality" in the aetiology of psychiatric and developmental disorders, as explicitly highlighted in CFB (PSY04) [4]. This contrasts with most psychiatric disorders, which are multifactorial.
2. Epidemiology
| Parameter | Value |
|---|---|
| Full mutation prevalence in males | 1 in 4,000 – 1 in 7,000 [2] |
| Full mutation prevalence in females | Approximately 1/2 to 2/3 of male prevalence (roughly 1 in 6,000 – 1 in 11,000) [2] |
| Premutation carrier rate in males | 1 in 750 – 850 [2] |
| Premutation carrier rate in females | 1 in 250 – 300 [2] |
| Male-to-female clinical expression ratio | ~2:1 (males more severely affected) [1] |
-
Why males are more severely affected than females: Males have only one X chromosome (XY). If their single FMR1 gene carries the full mutation, they have zero functional copies → absent FMRP → fully affected. Females (XX) have two X chromosomes; even with a full mutation on one X, the other X may still produce some FMRP (depending on X-inactivation patterns). This is why 40–50% of female carriers can have learning difficulties, usually mild-to-moderate [1].
-
FXS is the most common inherited cause of intellectual disability – it is important to distinguish "inherited" from "most common genetic cause" (which is Down syndrome, usually arising de novo from meiotic non-disjunction rather than being inherited).
-
FXS accounts for approximately 2–3% of all intellectual disability and is present in ~5% of males with ID of unknown cause referred for genetic evaluation.
-
~10% of children with ASD have an identifiable genetic disorder, of which Fragile X syndrome is one of the most common [5][6].
Exam Pearl
When asked "What is the most common inherited cause of intellectual disability?" → Fragile X syndrome. When asked "What is the most common genetic cause of intellectual disability?" → Down syndrome (Trisomy 21). The distinction matters.
3. Anatomy and Function of FMR1/FMRP
- Location: Xq27.3 (long arm of X chromosome, band 27.3) [1][2]
- Normal function: Encodes FMRP (Fragile X Messenger Ribonucleoprotein) – previously called "Fragile X Mental Retardation Protein"
- The 5' untranslated region (5' UTR) of the FMR1 gene contains a CGG trinucleotide repeat tract
- Normal individuals have approximately 5–44 CGG repeats [1][2]
FMRP is an RNA-binding protein that is highly expressed in the brain (especially in neurons of the hippocampus, cortex, and cerebellum) and in the testes. Its functions include:
-
Synaptic plasticity regulation: FMRP acts as a translational repressor – it binds to mRNA at synapses and controls which proteins are made locally at the synapse. This is critical for activity-dependent synaptic remodelling (the process by which synapses strengthen or weaken in response to neuronal activity – the basis of learning and memory).
-
Dendritic spine maturation: FMRP regulates dendritic spine morphology. Without FMRP, dendritic spines are immature, long, thin, and tortuous (resembling immature/fetal spines) rather than the normal short, mushroom-shaped mature spines → this leads to aberrant synaptic connectivity → impaired learning and cognitive function.
-
mGluR5 signalling pathway: FMRP normally acts as a "brake" on metabotropic glutamate receptor 5 (mGluR5)-mediated protein synthesis at the synapse. Without FMRP, there is excessive mGluR5-driven signalling → excessive long-term depression (LTD) → synaptic dysfunction. This is the basis of the "mGluR theory of Fragile X", which has driven therapeutic research.
-
Other tissues: FMRP is also expressed in testes (relevant to macro-orchidism) and connective tissues (relevant to joint laxity, mitral valve prolapse).
Why Does Absent FMRP Cause Intellectual Disability?
Think of FMRP as the "quality control officer" at the synapse. It ensures that only the right proteins are synthesised at the right time in response to neuronal activity. Without this quality control, there is unregulated, excessive protein synthesis at the synapse → abnormal synapse formation and plasticity → the brain cannot properly encode, store, or retrieve learned information → intellectual disability.
4. Aetiology and Pathophysiology
GC Lecture High Yield
Trinucleotide repeat expansion is an unusual genetic mechanism where an unstable expansion of a trinucleotide repeat sequence (TRS) causes disease. The severity depends on whether the repeat is in a coding vs. non-coding region of the gene [1][3]:
- In coding sequence: produces a protein with excess amino acids (e.g., polyglutamine) → toxic protein → neurodegeneration (e.g., Huntington disease, spinocerebellar ataxia)
- In non-coding sequence: ↓ protein production (e.g., Fragile X syndrome, Friedreich ataxia)
- Severity ↑ upon generations because triplet repeats expand between subsequent generations → this is called anticipation [1][3]
FXS is caused by expansion of CGG repeats in the 5' untranslated region (non-coding) of the FMR1 gene → this is in the non-coding region, so the mechanism is ↓/absent FMRP production (not toxic protein) [1][2].
| Category | CGG Repeat Number | Molecular Consequence | Clinical Significance |
|---|---|---|---|
| Normal | ~5–44 | Normal FMRP production | Unaffected |
| Intermediate (Grey zone) | 45–54 | Stable or mildly unstable | Usually unaffected; may expand in offspring |
| Premutation | ~55–200 | FMR1 gene remains transcriptionally active; FMRP is produced | Classic FXS phenotype does NOT occur; but associated with a spectrum of clinical findings (FXTAS, FXPOI) [2] |
| Full mutation | > 200 | Hypermethylation of FMR1 → transcriptional silencing → absent FMRP | Classic FXS phenotype [1][2] |
CGG repeats expand beyond ~200
↓
5' UTR region becomes abnormally long
↓
Triggers HYPERMETHYLATION of CpG islands in the FMR1 promoter region
↓
DNA methylation = epigenetic silencing (methyl groups physically block
transcription factors from binding → gene is "turned off")
↓
FMR1 gene is SILENCED → no mRNA transcribed
↓
No FMRP produced
↓
Loss of translational regulation at synapses
↓
Excessive unregulated protein synthesis → abnormal dendritic spines
→ impaired synaptic plasticity → intellectual disability
+ Effects on connective tissue, testes, cardiac valvesAlmost all (99%) cases of FXS are caused by trinucleotide repeat expansion; rare causes include point mutations, deletions, or missense mutations in FMR1 [1][2].
This is a crucial concept. Premutation carriers (55–200 repeats) do NOT have absent FMRP. Instead, their FMR1 gene is transcriptionally active – in fact, it is overactive. The expanded CGG repeat leads to elevated FMR1 mRNA levels (2–8 times normal). This excess mRNA itself is toxic (RNA gain-of-function toxicity), leading to distinct premutation-associated conditions:
| Premutation Condition | Who Is Affected | Pathophysiology |
|---|---|---|
| Fragile X-associated Tremor/Ataxia Syndrome (FXTAS) [1] | Males > 50 years (occasionally females) | Toxic mRNA forms nuclear inclusions in neurons and astrocytes → progressive cerebellar ataxia, intention tremor, cognitive decline, parkinsonism |
| Fragile X-associated Primary Ovarian Insufficiency (FXPOI) | Female premutation carriers | Toxic mRNA damages ovarian follicles → premature menopause (before age 40) in ~20% of female premutation carriers |
| Neurodevelopmental issues | Children with premutation | Some may have ADHD, anxiety, or mild learning difficulties (though most are cognitively normal) |
Full Mutation vs. Premutation – Different Mechanisms!
A common exam mistake is conflating premutation and full mutation. They have fundamentally different molecular mechanisms:
- Full mutation ( > 200 repeats): Gene is silenced → absent protein (loss of function)
- Premutation (55–200 repeats): Gene is overactive → excess mRNA (RNA toxicity/gain of function) The clinical phenotypes are therefore completely different.
FXS is classified as X-linked [1][4], but its inheritance pattern is unusual due to the dynamic nature of trinucleotide repeat expansion.
Key inheritance principles:
-
CGG repeats are unstable during meiosis (especially during oogenesis/maternal transmission). They tend to expand when passed from parent to child.
-
The larger the premutation, the more likely it is to expand to a full mutation in the next generation. A mother with a premutation of 90 repeats has a much higher risk (~80%) of her child having a full mutation than a mother with 60 repeats (~5%).
-
Hence a male can be unaffected (normal transmitting male with premutation), then transmit to his daughter (who becomes a premutation carrier), and the grandson may be affected with the full mutation [1]. This is the Sherman Paradox – the observation that the risk of being affected increases in later generations.
-
Paternal transmission: When a premutation father passes his X chromosome to a daughter, the CGG repeat tends NOT to expand to a full mutation (repeats are relatively stable during spermatogenesis). So daughters of premutation males are virtually always premutation carriers, not fully affected.
-
Maternal transmission: When a premutation mother passes her X chromosome, the CGG repeat CAN expand to a full mutation → affected child. The risk depends on the size of the mother's premutation.
GC Lecture Slide – Sample Genetic Report
The GC 151 lecture slide [3] shows a clinical genetics letter for a boy named Lee Yan (DOB 10-1-1999) diagnosed with Fragile X syndrome:
- Chromosomal studies showed normal karyotype (46,XY) – this is important! Standard karyotyping does NOT detect FXS. The fragile site is only seen under special culture conditions and molecular testing is the gold standard.
- 300 CGG repeats were found in the FMR1 gene (full mutation, confirming FXS)
- 65 CGG repeats found in his mother (premutation range – she is a carrier)
- Maternal family members should be seen for genetic counselling – because other maternal relatives may carry the premutation/full mutation. This slide illustrates that FXS requires molecular analysis of CGG repeats, not standard karyotyping [3].
In every female cell, one of the two X chromosomes is randomly inactivated (lyonisation). In a female with the full mutation:
- If the normal X is preferentially active in most cells → she produces adequate FMRP → may be minimally or unaffected
- If the mutant X is preferentially active in most cells → she produces little FMRP → more significantly affected
This explains the wide variation in degree of impairment in females with full mutation [2]. The "activation ratio" (proportion of cells with the normal X active) correlates with cognitive outcome.
5. Classification
| Classification | CGG Repeats | Key Features |
|---|---|---|
| Normal | 5–44 | No clinical significance |
| Intermediate | 45–54 | May be unstable; genetic counselling may be offered |
| Premutation | 55–200 | Risk of FXTAS (males), FXPOI (females), risk of expansion to full mutation in offspring |
| Full mutation | > 200 | Classic FXS phenotype |
- Mosaicism can occur (some cells have methylated full mutation, others have unmethylated premutation or even normal alleles) → these individuals may have milder phenotypes
- IQ range in affected males: 20–80, mean ~50 (moderate to severe ID) [1]
| Condition | Population | Mechanism |
|---|---|---|
| Fragile X Syndrome (FXS) | Children (both sexes, males > females) | Full mutation → absent FMRP |
| FXTAS | Older adults (males > 50y) with premutation | RNA toxicity from excess FMR1 mRNA |
| FXPOI | Adult females with premutation | RNA toxicity → ovarian damage |
6. Clinical Features
The clinical features of FXS are age-dependent. In early childhood, the phenotype may be subtle – intellectual disability or developmental delay is often the presenting feature. The classical physical features become more apparent with age, especially after puberty.
| Symptom | Pathophysiological Basis | Age of Presentation |
|---|---|---|
| Developmental delay / Intellectual disability | Absent FMRP → impaired synaptic plasticity and dendritic spine maturation → deficient learning and memory circuits | Infancy onwards (may be the first concern) |
| Speech and language delay | Disproportionately affected; FMRP is crucial for language network development; often cluttered, repetitive speech ("litany-like") | Toddler years |
| Learning difficulties (especially maths, executive function) | FMRP required for frontal lobe-dependent executive function and working memory | School age |
| Autistic features / ASD | ~30% of males with FXS meet DSM-5 criteria for ASD; FMRP regulates synaptic proteins implicated in ASD pathways (e.g., SHANK3, neuroligins) [5][6] | Early childhood |
| ADHD symptoms (inattention, hyperactivity, impulsivity) | Dysregulated catecholamine signalling due to absent FMRP modulation of dopaminergic/noradrenergic circuits | Preschool – school age |
| Anxiety (social anxiety, selective mutism, generalised anxiety) | Amygdala hyperreactivity – FMRP normally dampens amygdala responses to social/sensory stimuli; without it, there is exaggerated fear response | Childhood, may worsen in adolescence |
| Sensory hypersensitivity (tactile defensiveness, hyperacusis) | Aberrant sensory processing due to unregulated synaptic excitability (excessive mGluR5 signalling) | Early childhood |
| Gaze aversion | Social anxiety + sensory overload from eye contact (distinct from ASD gaze aversion – in FXS, children are socially interested but avoidant) | Early childhood |
| Hand flapping, hand biting | Stereotypic behaviours; overlap with ASD; likely related to sensory self-stimulation | Toddler – childhood |
| Sleep disturbances | Dysregulated melatonin production; FMRP involved in circadian rhythm gene regulation | Infancy onwards |
| Seizures (~10–20% of males with FXS) | FMRP regulates GABA and glutamate receptor expression; its absence creates an excitation-inhibition imbalance favouring excitability | Childhood; often benign, may remit by adolescence [7] |
6B. Signs (What the clinician observes on examination)
| Sign | Pathophysiological Basis | Notes |
|---|---|---|
| Macrocephaly | FMRP involved in regulating brain growth; its absence leads to accelerated brain growth in early childhood | Head circumference often > 97th centile; brain MRI may show increased caudate volume |
| Long face with broad forehead | Connective tissue dysplasia due to absent FMRP (FMRP regulates extracellular matrix protein expression) | Becomes more prominent with age |
| Large, everted (prominent) ears | Same connective tissue mechanism; ears appear "cupped" or "bat-like" | One of the most recognisable features; present from infancy |
| Prominent mandible (prognathism) | Connective tissue laxity + possibly altered growth factor regulation in craniofacial development | More evident after puberty |
| High-arched palate | Connective tissue dysplasia | May contribute to feeding difficulties in infancy |
| Sign | Pathophysiological Basis | Notes |
|---|---|---|
| Joint laxity (hyperextensibility) | FMRP regulates elastin and collagen-related gene expression; absent FMRP → connective tissue weakness | Especially finger joints; may resemble Ehlers-Danlos phenotype |
| Flat feet (pes planus) | Ligamentous laxity of the foot arches | Common |
| Scoliosis | Connective tissue laxity + hypotonia → vertebral malalignment | May require monitoring |
| Soft, velvet-like skin | Connective tissue dysplasia |
| Sign | Pathophysiological Basis | Notes |
|---|---|---|
| Macro-orchidism | FMRP normally regulates Sertoli cell proliferation and seminiferous tubule development; its absence leads to excessive Sertoli cell proliferation → testicular enlargement. Not due to increased testosterone. | Develops after puberty (testicular volume > 30 mL, normal adult is 15–25 mL); present in > 80% of post-pubertal males [1] |
| Sign | Pathophysiological Basis | Notes |
|---|---|---|
| Mitral valve prolapse (MVP) | Connective tissue dysplasia → myxomatous degeneration of mitral valve leaflets (similar mechanism to Marfan syndrome) | Present in ~50% of adults with FXS; usually mild; may cause mid-systolic click on auscultation [1] |
| Aortic root dilatation | Connective tissue abnormality (less common) | Rare |
| Sign | Pathophysiological Basis | Notes |
|---|---|---|
| Intellectual disability: moderate-severe in males (IQ 20–80, mean ~50) | See above – synaptic dysfunction | Females typically milder (IQ may be normal or borderline) [1] |
| Hypotonia (in infancy) | CNS + connective tissue involvement | May present as "floppy infant" |
| Motor clumsiness / coordination difficulties | Cerebellar involvement (FMRP expressed in Purkinje cells) | |
| Perseverative speech | Executive function impairment (frontal lobe dysfunction) | Repeating phrases, echolalia |
| Fragile X-associated tremor/ataxia syndrome (FXTAS) | RNA toxicity from premutation – NOT from full mutation | Occurs in older adults with premutation, not children with FXS [1] |
| Age Group | Key Features |
|---|---|
| Neonate/infant | May be normal at birth; subtle hypotonia, large head, feeding difficulties, prominent ears may be noted. Often NOT diagnosed at this stage unless there is a family history. |
| Toddler (1–3 years) | Developmental delay becomes evident (especially speech/language); hand flapping; may be referred for ASD evaluation |
| Preschool (3–5 years) | ADHD symptoms emerge; anxiety; learning difficulties become more apparent |
| School age (6–12 years) | ID becomes clearly defined; seizures may occur; behavioural challenges; facial features become more recognisable |
| Adolescence/post-puberty | Macro-orchidism develops; facial features most prominent (long face, prominent jaw); MVP may be detected; seizures often remit |
~40–50% of females with the full mutation have some degree of learning difficulty, but this is typically mild to moderate [1]. The variability depends on X-inactivation patterns:
- ~25% have normal IQ but may still have executive function difficulties, anxiety, or social difficulties
- ~25% have borderline IQ (70–84)
- ~25% have mild ID
- Physical features are usually milder or absent
| Domain | Features | Mechanism |
|---|---|---|
| Craniofacial | Macrocephaly, long face, broad forehead, large everted ears, prominent mandible | Connective tissue dysplasia + abnormal brain growth |
| Neurological | Moderate-severe ID (males), learning difficulties, ASD, ADHD | Absent FMRP → synaptic dysfunction |
| Behavioural | Anxiety, gaze aversion, hand flapping, sensory hypersensitivity | Amygdala hyperreactivity + sensory processing dysfunction |
| Musculoskeletal | Joint laxity, scoliosis, flat feet | Connective tissue dysplasia |
| Genital | Macro-orchidism (post-pubertal) | Sertoli cell proliferation |
| Cardiovascular | MVP | Myxomatous valve degeneration |
| Seizures | ~10–20%, often remit by adolescence | Excitation-inhibition imbalance |
7. Family-Centred Care and Communication Considerations
- FXS is often diagnosed after a period of diagnostic uncertainty ("diagnostic odyssey") – parents may have noticed developmental delay but not received answers. Be empathetic about this journey.
- Explain the X-linked inheritance clearly using diagrams – mothers who are carriers often feel guilt. Emphasise that this is not anyone's "fault."
- Genetic counselling for the maternal family is essential [3] – maternal aunts, grandmothers, and cousins may carry the premutation/full mutation and may be at risk for FXTAS, FXPOI, or having affected children.
- Prenatal and preimplantation genetic testing is available for future pregnancies.
- For genetic testing in children, parental consent is obtained. In adolescents, assent should be sought where cognitively appropriate.
- Cascade genetic testing of other family members should be offered with genetic counselling support.
High Yield Summary
Fragile X Syndrome – Key Points for Exams:
- Most common inherited cause of intellectual disability (distinguish from Down syndrome, which is the most common genetic cause overall)
- X-linked; FMR1 gene at Xq27.3; CGG trinucleotide repeat expansion in the 5' UTR (non-coding region)
- 99% caused by trinucleotide repeat expansion → hypermethylation → absent FMRP
- Repeat ranges: Normal (~5–44), Premutation (55–200), Full mutation ( > 200)
- Full mutation: gene silenced → no FMRP → loss of function
- Premutation: gene overactive → excess mRNA → RNA toxicity (FXTAS, FXPOI)
- Anticipation: repeats expand through generations (especially maternal transmission)
- Sherman Paradox: unaffected male → carrier daughter → affected grandson
- Clinical triad: Intellectual disability + Large ears/long face + Macro-orchidism (after puberty)
- Associated features: ASD (~30%), ADHD, anxiety, joint laxity, MVP, seizures (10–20%)
- Females: 40–50% with full mutation have learning difficulty (variable due to X-inactivation)
- Diagnosis: Molecular analysis of CGG repeat number in FMR1 (NOT standard karyotype)
- Standard karyotype is NORMAL (46,XY) – fragile site only seen under special conditions
- Genetic counselling of maternal relatives is mandatory
Active Recall - Fragile X Syndrome
[1] Senior notes: Adrian Lui Pediatrics Notes.pdf (pp. 496–497) [2] Senior notes: MBBS Final MB (Pediatrics) (Felix PY Lai).pdf (pp. 880–881) [3] GC Lecture slides: GC 151. The malformed child hereditary syndromes and anomalies.pdf (p. 26) [4] GC Lecture slides: CFB (PSY04) Aetiology of Psychiatric Disorders.pdf (p. 8) [5] Senior notes: Adrian Lui Pediatrics Notes.pdf (p. 86) – ASD aetiology section [6] Senior notes: Ryan Ho Psychiatry.pdf (p. 256) – ASD aetiology section [7] Senior notes: Ryan Ho Neurology.pdf (p. 102) – Genetic aetiology of epilepsy
Differential Diagnosis of Fragile X Syndrome
A child presenting with features suggestive of FXS — developmental delay, intellectual disability (ID), behavioural concerns (ASD/ADHD features), and/or characteristic dysmorphic features — sits within a broad differential. The key clinical challenge is that many of these features are non-specific in early childhood. A toddler with speech delay and hypotonia could have dozens of possible diagnoses. The classic FXS triad (ID + long face with large ears + macro-orchidism) is often only fully apparent after puberty — so in the younger child, you must differentiate FXS from other causes of global developmental delay (GDD), intellectual disability, and syndromic/dysmorphic presentations.
The differential diagnosis can be organised along several clinical axes:
- Child presenting with GDD / intellectual disability (the most common presentation of FXS)
- Child presenting with ASD / behavioural phenotype
- Child presenting with specific dysmorphic features (long face, large ears, macro-orchidism, joint laxity)
- Child with connective tissue features (joint laxity, MVP, tall habitus)
The approach depends on the presenting feature. In practice, a child with FXS most often presents with:
- Developmental delay or intellectual disability (most common referral reason)
- Behavioural concerns (ASD, ADHD, anxiety)
- Family history of intellectual disability or known FXS/premutation
Less commonly, the presentation is triggered by recognition of dysmorphic features or macro-orchidism (post-pubertal).
7B. Differential Diagnosis Table — Organised by Clinical Overlap
These are the conditions most likely to be confused with FXS in a paediatric genetics or developmental paediatrics clinic.
| Condition | Genetic Basis | Overlapping Features with FXS | Distinguishing Features | Key Investigation |
|---|---|---|---|---|
| Down Syndrome (Trisomy 21) | Trisomy 21 (47,XX/XY,+21) | ID (usually mild-moderate), hypotonia, ASD in some, congenital heart disease | Flat face, upslanting palpebral fissures, epicanthic folds, single palmar crease, Brushfield spots, short stature, AVSD most common cardiac defect [8] | Karyotype / FISH / CMA |
| Sotos Syndrome ("cerebral gigantism") | NSD1 gene (5q35), AD | Macrocephaly, ID (usually mild), long face, behavioural difficulties (ADHD, anxiety), advanced bone age | Overgrowth (tall stature with macrocephaly from birth), prominent forehead, sparse frontotemporal hair, pointed chin, downslanting palpebral fissures | NSD1 gene testing |
| Williams Syndrome | 7q11.23 microdeletion (elastin gene) | ID (mild), "cocktail party" personality (superficially sociable but impaired social cognition), joint laxity, cardiac involvement | Elfin facies (broad forehead, short nose, long philtrum, full lips), supravalvular aortic stenosis, peripheral PS, transient neonatal hypercalcaemia, renal artery stenosis, hypertension [9] | FISH / CMA for 7q11.23 deletion |
| Noonan Syndrome | RAS-MAPK pathway genes (PTPN11 most common), AD | Short stature, ID (mild in ~25%), cardiac involvement, joint laxity | Turner-like phenotype in both sexes: hypertelorism, ptosis, low-set ears, webbed neck, shield chest, right-sided cardiac lesions (pulmonary stenosis, HCM), cryptorchidism, bleeding tendency [8][9] | Gene panel (RASopathy genes) |
| Angelman Syndrome | Loss of maternal UBE3A (15q11-q13) | ID (severe), ASD features, seizures (~90%), happy demeanour | Severe ID with absent speech, ataxic gait ("puppet-like"), inappropriate laughter, microcephaly, seizure onset typically 1–3 years | Methylation analysis of 15q11-q13 |
| Prader-Willi Syndrome | Loss of paternal 15q11-q13 | Hypotonia (infancy), ID (mild-moderate), behavioural difficulties | Neonatal hypotonia with poor feeding → then hyperphagia and obesity (from ~2 years), short stature, hypogonadism, small hands and feet | Methylation analysis of 15q11-q13 |
| Rett Syndrome | MECP2 mutation (Xq28), X-linked dominant | Predominantly females, ASD-like features, ID, seizures | Normal development until 6–18 months then regression, loss of purposeful hand movements (hand-wringing stereotypies), gait apraxia, deceleration of head growth | MECP2 gene testing |
| Klinefelter Syndrome (47,XXY) | 47,XXY | ID (mild), tall stature, behavioural difficulties, small testes (cf. FXS: large testes) | Tall stature, eunuchoid habitus, small firm testes, gynecomastia, infertility (azoospermia), hypergonadotropic hypogonadism; usually presents in adolescence/adulthood [10] | Karyotype |
| Turner Syndrome | 45,X (or variants) | Short stature, cardiac involvement, learning difficulties (non-verbal LD), webbed neck | Female only, short stature, shield chest, lymphoedema, coarctation of aorta, bicuspid aortic valve, streak gonads, primary amenorrhoea [10] | Karyotype |
Exam Pearl – Sotos vs. FXS
Both Sotos syndrome and FXS cause macrocephaly + ID + long face. The key distinguisher is that Sotos has overgrowth (tall stature + advanced bone age), whereas FXS has normal to slightly tall stature with macro-orchidism after puberty. Sotos also has a pointed chin and sparse frontotemporal hair, features NOT seen in FXS.
Because FXS causes connective tissue features (joint laxity, MVP, flat feet, scoliosis), it can overlap with:
| Condition | Genetic Basis | Overlapping Features with FXS | Distinguishing Features | Key Investigation |
|---|---|---|---|---|
| Marfan Syndrome | FBN1 gene (15q21.1), AD | Joint hypermobility, MVP, scoliosis, flat feet, long face | Tall stature with disproportionately long limbs (arm span > height), arachnodactyly, ectopia lentis (upward lens subluxation ~60%), aortic root dilatation/dissection, pectus deformity; NO intellectual disability [1][9] | Revised Ghent criteria; FBN1 gene testing |
| Ehlers-Danlos Syndrome (hypermobile type) | Various (COL5A1/A2 for classical; mostly unknown for hypermobile type) | Joint hypermobility, soft skin, MVP | Skin hyperextensibility, tissue fragility (easy bruising, poor wound healing), no ID, no characteristic facial features | Clinical (Beighton score); gene testing for classical type |
| Loeys-Dietz Syndrome | TGFBR1/TGFBR2, AD | MVP, joint laxity, scoliosis | Bifid uvula/cleft palate, hypertelorism, arterial tortuosity, aggressive aortic aneurysms; no ID | TGFBR gene testing |
Key Differentiator: Marfan vs. FXS
Both can present with tall stature, joint laxity, MVP, flat feet, and scoliosis. However:
- Marfan: NO intellectual disability; HAS ectopia lentis and aortic root dilatation
- FXS: HAS intellectual disability and macro-orchidism; NO ectopia lentis The presence or absence of ID and lens subluxation is the clinical separator [1].
~30% of males with FXS meet criteria for ASD [5][6]. When a child presents primarily with autistic features, consider:
| Condition | Genetic Basis | Overlapping Features | Distinguishing Features |
|---|---|---|---|
| Idiopathic ASD | Polygenic / multifactorial | ASD behaviours, speech delay, ADHD, sensory issues | No dysmorphic features, no ID (in ~50% of ASD), no macro-orchidism; diagnosed clinically by DSM-5 criteria |
| Tuberous Sclerosis Complex (TSC) | TSC1 (hamartin) / TSC2 (tuberin), AD | ASD (~40%), ID, seizures | Ash-leaf spots, facial angiofibromas, shagreen patch, cortical tubers on MRI, cardiac rhabdomyomas |
| Rett Syndrome | MECP2, X-linked dominant | ASD-like features, stereotypies, seizures | Regression after 6–18 months; hand-wringing; almost exclusively females |
| PTEN hamartoma syndrome | PTEN gene, AD | Macrocephaly, ASD, ID | Extreme macrocephaly (head circumference > 98th centile), hamartomas, increased cancer risk |
| 22q11.2 Deletion Syndrome (DiGeorge) | 22q11.2 microdeletion | ID (mild-borderline), behavioural difficulties, psychiatric features | Conotruncal cardiac defects (ToF, truncus arteriosus, interrupted aortic arch), thymic hypoplasia, hypocalcaemia, palatal anomalies [8] |
High Yield – GC/Block C Lecture Point
Fragile X syndrome is listed alongside Down syndrome, muscular dystrophy, neurofibromatosis, and tuberous sclerosis as a genetic disorder associated with ASD (accounting for ~10% of ASD cases) [5][6]. When a child presents with ASD, it is important to consider these syndromic causes — particularly if there are dysmorphic features, family history of ID, or seizures — as they change genetic counselling, prognosis, and management.
~10–20% of males with FXS have seizures [1][7]. Other genetic conditions causing seizures + ID include:
| Condition | Key Features Distinguishing from FXS |
|---|---|
| Angelman Syndrome | Severe ID with absent speech, ataxic gait, seizures (~90%), happy demeanour, microcephaly (cf. FXS: macrocephaly) |
| Dravet Syndrome (SCN1A) | Severe myoclonic epilepsy of infancy; fever-triggered seizures from ~6 months; progressive cognitive decline |
| Rett Syndrome | Regression, hand-wringing, almost exclusively female |
| Tuberous Sclerosis | Infantile spasms, cortical tubers, skin lesions |
| Category | Examples | Distinguishing from FXS |
|---|---|---|
| Perinatal insult | Hypoxic-ischaemic encephalopathy, prematurity-related brain injury | History of difficult delivery, NICU stay; brain MRI shows acquired injury |
| Metabolic disorders | Phenylketonuria (PKU), hypothyroidism, storage disorders | Newborn screening positive; specific biochemical markers; may have regression |
| Environmental | Fetal alcohol spectrum disorder (FASD), lead poisoning | Maternal alcohol history; smooth philtrum, thin upper lip, short palpebral fissures (FASD); blood lead levels |
| Chromosomal microarray abnormalities | Various copy number variants (CNVs) | Detected on CMA; variable phenotypes; no specific FXS features |
| Fanconi Anaemia | Short stature, radial ray anomalies, café-au-lait spots, pancytopenia [11] | Bone marrow failure; chromosome breakage study positive |
| Neurofibromatosis Type 1 | Café-au-lait macules, neurofibromas, Lisch nodules, learning difficulties (but NOT usually moderate-severe ID) [12] | ≥ 2/8 CAFESPOT criteria; NF1 gene testing |
| Clinical Question | Points Towards FXS | Points Away from FXS |
|---|---|---|
| Family history pattern? | X-linked: affected males on maternal side; females with mild LD; Sherman paradox | De novo (Down, many Marfan); AD pedigree (NF1, Marfan, Noonan); maternal inheritance only (mitochondrial) |
| Head size? | Macrocephaly | Microcephaly (Angelman, Rett); normal (most other conditions) |
| Facial features? | Long face, large everted ears, prominent mandible, broad forehead | Flat face + epicanthic folds (Down); elfin facies (Williams); pointed chin (Sotos) |
| Testicular size (post-pubertal)? | Macro-orchidism ( > 25 mL) | Small testes (Klinefelter, Prader-Willi); normal (most others) |
| Connective tissue signs? | Joint laxity, flat feet, MVP, scoliosis | Ectopia lentis + aortic root (Marfan); skin fragility (EDS) |
| Behavioural phenotype? | Social anxiety with gaze aversion (but socially interested), hand flapping, cluttered speech | Complete social disinterest (severe ASD); regression (Rett); hyperphagia (Prader-Willi) |
| Regression? | No regression (skills acquired slowly; apparent "decline" is slowing of acquisition relative to peers, not true loss) [2] | True regression → think Rett, metabolic/storage disorders, Dravet |
| Karyotype? | Normal (46,XY or 46,XX) [3] | Abnormal (Down: trisomy 21; Turner: 45,X; Klinefelter: 47,XXY) |
Critical Point – FXS Does NOT Cause Regression
Cognitive level and adaptive behaviour skills decline after early childhood, reflecting the slow acquisition of skills compared with other children of the same age rather than a regression of skills [2]. This is a subtle but important distinction. True regression (loss of previously acquired skills) should prompt investigation for Rett syndrome, metabolic/neurodegenerative disorders, or epileptic encephalopathy — not FXS.
Indications for molecular testing for FXS [2]:
In children:
- Developmental delay
- Borderline intellectual abilities or intellectual disabilities
- Diagnosis of autism without a specific aetiology
In adults:
- Females with primary ovarian insufficiency (POI)
- Patients > 50 years old with progressive cerebellar ataxia and intention tremor (FXTAS)
- Adults with typical physical features and intellectual disability without a specific aetiology
High Yield – Indications for FXS Testing
The lecture slides and senior notes emphasise that any child with unexplained GDD/ID or ASD should be considered for FXS molecular testing [2][3]. This is particularly true if there is a family history of intellectual disability, premature ovarian failure, or tremor/ataxia in maternal relatives. Standard karyotyping will NOT detect FXS — molecular analysis (CGG repeat sizing) is required [3].
High Yield for Exams — When asked "What is the differential diagnosis of Fragile X syndrome?", think of conditions that share the core features of FXS:
| Rank | Condition | Why It Overlaps | Key Differentiator |
|---|---|---|---|
| 1 | Sotos Syndrome | Macrocephaly + long face + ID | Overgrowth, advanced bone age, pointed chin |
| 2 | Down Syndrome | Most common genetic cause of ID; hypotonia, ASD | Flat face, upslanting eyes, AVSD, trisomy 21 on karyotype |
| 3 | Idiopathic ASD | Behavioural overlap (30% of FXS meets ASD criteria) | No dysmorphism, no macro-orchidism, no connective tissue features |
| 4 | Marfan Syndrome | Joint laxity, MVP, tall habitus, long face | Ectopia lentis, aortic root dilatation, NO ID |
| 5 | Angelman Syndrome | Severe ID, seizures, happy demeanour | Absent speech, microcephaly (vs. macrocephaly in FXS), ataxic gait |
Active Recall - Differential Diagnosis of Fragile X Syndrome
References
[1] Senior notes: Adrian Lui Pediatrics Notes.pdf (pp. 458, 497) [2] Senior notes: MBBS Final MB (Pediatrics) (Felix PY Lai).pdf (pp. 880, 882–883) [3] GC Lecture slides: GC 151. The malformed child hereditary syndromes and anomalies.pdf (p. 26) [5] Senior notes: Adrian Lui Pediatrics Notes.pdf (p. 86) [6] Senior notes: Ryan Ho Psychiatry.pdf (pp. 251, 256) [7] Senior notes: Ryan Ho Neurology.pdf (p. 102) [8] Senior notes: Ryan Ho Cardiology.pdf (p. 185) [9] Senior notes: Maksim Paediatric Notes.pdf (p. 207) [10] Senior notes: Adrian Lui Pediatrics Notes.pdf (p. 507) [11] Senior notes: Block A - Pallor_ diagnosis of anaemia; nutritional anaemia; anaemia of systemic diseases.pdf (p. 42) [12] Senior notes: Ryan Ho Rheumatology.pdf (p. 172)
Diagnostic Criteria, Diagnostic Algorithm, and Investigations for Fragile X Syndrome
Unlike many paediatric conditions (e.g., Kawasaki disease, rheumatic fever) that use clinical diagnostic criteria based on a combination of signs and symptoms, Fragile X syndrome is definitively diagnosed by molecular genetic testing. The clinical features — intellectual disability, characteristic facies, macro-orchidism, behavioural phenotype — are supportive and raise suspicion, but the diagnosis is confirmed (or excluded) by demonstrating the CGG repeat expansion in the FMR1 gene [1][2][3].
This is because:
- The clinical phenotype is age-dependent and often subtle in young children — the very population in whom early diagnosis matters most for intervention.
- Many features (developmental delay, hypotonia, large ears) are non-specific and shared by numerous other conditions (see DDx section).
- Standard karyotyping (46,XY or 46,XX) is NORMAL in FXS [3] — the "fragile site" on the X chromosome is only visible under special folate-depleted culture conditions and is no longer used as a diagnostic method.
GC Lecture Slide – Critical Exam Point
The GC 151 lecture slide [3] explicitly demonstrates a clinical genetics report where:
- Chromosomal studies showed normal karyotype (46,XY)
- Diagnosis was made by molecular analysis: 300 CGG repeats in FMR1
- Mother had 65 CGG repeats (premutation carrier)
This reinforces that karyotyping does NOT diagnose FXS — molecular testing for CGG repeat number is mandatory [3].
8B. Indications for Molecular Testing — Who Should Be Tested?
The most important clinical decision is recognising which children and adults warrant FXS molecular testing. Testing should be considered in the following situations [2]:
| Clinical Scenario | Why Test? |
|---|---|
| Developmental delay (any domain) | FXS is the most common inherited cause of ID; early diagnosis enables early intervention [2] |
| Borderline intellectual abilities or intellectual disability of unknown aetiology | Must exclude FXS before labelling as "idiopathic" |
| Autism spectrum disorder without a specific identified aetiology | ~2–6% of children with ASD have FXS; FXS is the most common single-gene cause of ASD [2][5] |
| Family history of intellectual disability (especially males on the maternal side) | X-linked pattern suggests FXS |
| Family history of premature ovarian insufficiency or tremor/ataxia in maternal relatives | Suggests premutation carrier status in the family |
| Characteristic physical features (macrocephaly, large ears, long face, joint laxity) ± ID | Clinical suspicion warrants confirmation |
| Clinical Scenario | Why Test? |
|---|---|
| Females with primary ovarian insufficiency (POI) | ~20% of female premutation carriers develop FXPOI [2] |
| Patients > 50 years with progressive cerebellar ataxia and intention tremor | Consider FXTAS in premutation carriers [2] |
| Adults with typical physical features and ID without a specific aetiology | May have been undiagnosed in childhood |
High Yield – When to Order FXS Testing
Any child with unexplained GDD, intellectual disability, or ASD should be considered for FXS molecular testing [2]. This is a standard part of the first-tier genetic workup for unexplained developmental delay in paediatric practice. Many guidelines now recommend FXS testing alongside chromosomal microarray (CMA) as the initial genetic investigations for unexplained GDD/ID.
The following algorithm outlines the clinical and laboratory pathway from suspicion to confirmed diagnosis and subsequent management steps.
8D. Investigation Modalities, Key Findings, and Interpretation
I. Primary Diagnostic Test: FMR1 Molecular Analysis
| Parameter | Detail |
|---|---|
| Method | Polymerase chain reaction (PCR) with primers flanking the CGG repeat region in the 5' UTR of FMR1 |
| What it measures | Number of CGG repeats |
| Strength | Rapid, relatively inexpensive; accurately sizes alleles in the normal, intermediate, and premutation range |
| Limitation | Standard PCR cannot reliably amplify very large expansions ( > ~200 repeats) because the GC-rich repeat region forms stable secondary structures (hairpins) that block polymerase progression. A full mutation may therefore appear as a "blank" or absent allele on PCR |
| Interpretation of "absent allele" in a male | If a male shows no PCR product for FMR1, it suggests a very large expansion that PCR cannot amplify → must proceed to Southern blot |
| Triplet-primed PCR (TP-PCR) | A refinement that uses a primer within the repeat region, generating a characteristic "stutter" pattern on capillary electrophoresis. Can detect expansions into the premutation and full mutation range more reliably than standard PCR. Widely used as a screening tool |
| Parameter | Detail |
|---|---|
| Method | Genomic DNA is digested with restriction enzymes (e.g., EcoRI + EagI), separated by gel electrophoresis, transferred to membrane, hybridised with a labelled probe specific to the FMR1 region |
| What it measures | (1) Size of the CGG repeat expansion (including very large full mutations), and (2) Methylation status of the FMR1 promoter (EagI is a methylation-sensitive enzyme — it cuts unmethylated DNA but NOT methylated DNA) |
| Key findings | Normal male: single band at ~2.8 kb (EcoRI/EagI). Full mutation male: band shifts upward ( > 5.2 kb) due to expansion AND remains uncut by EagI (indicating methylation/gene silencing). Premutation: intermediate-sized band, cut by EagI (unmethylated, gene active) |
| Strength | Can size very large expansions; simultaneously determines methylation status (functionally important) |
| Limitation | Slower (takes days), requires more DNA, less widely available, more expensive than PCR |
In practice, most laboratories use a two-step approach:
- PCR (or TP-PCR) as the first-line screening test
- Southern blot if PCR suggests a large expansion (absent allele) or to confirm full mutation and assess methylation
Interpreting the Molecular Report
When you receive a molecular report for FXS, look for three pieces of information:
- CGG repeat number → determines the category (normal / intermediate / premutation / full mutation)
- Methylation status → determines whether the gene is silenced (functionally relevant)
- Mosaicism → some individuals have a mixture of premutation and full mutation cells (size mosaicism) or methylated and unmethylated full mutation cells (methylation mosaicism) → milder phenotype
| CGG Repeats | PCR Result | Southern Blot | Methylation | Clinical Significance |
|---|---|---|---|---|
| 5–44 | Normal-sized band | Normal (~2.8 kb) | Unmethylated | Normal; no FXS |
| 45–54 | Slightly enlarged | Slightly enlarged | Unmethylated | Intermediate; may be unstable in future generations; genetic counselling |
| 55–200 | Enlarged band visible | Intermediate size | Unmethylated (gene active) | Premutation carrier; risk of FXTAS/FXPOI; risk of expansion to full mutation in offspring |
| > 200 | Absent or smeared band ("blank allele" in males) | Large shifted band ( > 5.2 kb) | Methylated (gene silenced) | Full mutation = Fragile X syndrome confirmed |
| Mosaic | Variable | Mixed bands | Partially methylated | Size or methylation mosaicism; may have milder phenotype |
It is essential to understand what standard genetic tests will and will not show in FXS.
| Investigation | Expected Finding in FXS | Why It Doesn't Diagnose FXS |
|---|---|---|
| Standard karyotype | Normal (46,XY or 46,XX) [3] | The fragile site at Xq27.3 is only visible under special folate-depleted culture conditions (historical method, no longer used diagnostically). Standard G-banded karyotyping does not detect trinucleotide repeat expansions |
| Chromosomal microarray (CMA) | Normal (in 99% of FXS cases) | CMA detects copy number variants (deletions/duplications) but NOT trinucleotide repeat expansions. The rare 1% of FXS caused by FMR1 deletions may be detected by CMA, but the vast majority (99%) caused by CGG expansion will be missed |
| Whole exome/genome sequencing | May miss CGG repeat expansion | Standard short-read sequencing technologies have difficulty mapping repetitive regions. Newer long-read sequencing platforms can detect expansions, but this is not yet routine |
Common Exam Trap
A normal karyotype does NOT exclude Fragile X syndrome [3]. This is a commonly tested point. If you are told "karyotype is 46,XY, normal" in a boy with intellectual disability, FXS is NOT excluded — you must specifically request FMR1 CGG repeat analysis to investigate FXS. Similarly, a normal CMA does not exclude FXS.
Once FXS is confirmed, additional investigations are performed to assess complications and guide multidisciplinary management:
| Investigation | Purpose | Expected Findings in FXS | Age to Perform |
|---|---|---|---|
| Developmental assessment (e.g., Griffiths, Bayley scales) | Quantify cognitive, motor, language, adaptive function domains | Moderate-severe ID in males (IQ 20–80, mean ~50); mild-moderate in some females [1] | At diagnosis, then longitudinal |
| ASD-specific assessment (e.g., ADOS-2, ADI-R) | Screen for co-morbid ASD | ~30% of males with FXS meet ASD criteria | At diagnosis if behavioural features present |
| ADHD assessment (e.g., Conners rating scales) | Screen for ADHD | Very common (~80% of males have ADHD features) | School age |
| Echocardiography | Screen for mitral valve prolapse (MVP) | MVP in ~50% of adults; less common in children | At diagnosis, repeat in adolescence/adulthood [1] |
| EEG | If seizures suspected | May show epileptiform discharges; seizures in ~10–20% of males [1][7] | Only if clinical seizures or concern |
| Ophthalmology assessment | Screen for strabismus, refractive errors | Strabismus common [2] | At diagnosis |
| Audiology | Screen for hearing difficulties | Recurrent otitis media may cause conductive hearing loss | At diagnosis |
| Orthopaedic assessment | Joint laxity, scoliosis, flat feet | Joint hypermobility, pes planus, scoliosis [1] | At diagnosis, then longitudinal |
| Testicular volume measurement | Document macro-orchidism | Testicular volume > 25 mL post-puberty (Prader orchidometer) [2] | Puberty and beyond |
This is a mandatory part of the diagnostic pathway [3]. Once FXS is diagnosed in a child:
- Mother → test for premutation/full mutation carrier status (determines recurrence risk for future pregnancies)
- Maternal aunts, grandmother, female cousins → may carry premutation/full mutation; at risk for:
- Having affected children
- FXPOI (premature ovarian failure)
- FXTAS (in older males and occasionally females with premutation)
- Siblings → test to determine if also affected (may have milder/undiagnosed phenotype)
The GC 151 lecture slide explicitly states: "We would see the other maternal family members and discuss the impact of the disease on them in our genetic counseling clinic" [3].
For families with known FXS/premutation status, reproductive options include:
| Method | Timing | What It Tests | Notes |
|---|---|---|---|
| Chorionic villus sampling (CVS) | 10–13 weeks gestation | CGG repeat number + methylation status from placental tissue | Earlier result than amniocentesis; small risk of miscarriage (~0.5–1%) |
| Amniocentesis | 15–18 weeks gestation | CGG repeat number + methylation from amniotic fluid cells | Methylation status is more reliably interpreted than from CVS |
| Preimplantation genetic testing (PGT-M) | Before implantation (IVF required) | Tests embryos for CGG expansion prior to transfer | Avoids need for pregnancy termination decision; technically challenging due to repeat instability |
| Non-invasive prenatal testing (NIPT) | From ~10 weeks gestation | Cell-free fetal DNA in maternal blood | NOT routinely used for FXS (repeat expansions are difficult to detect in cfDNA); research use only |
Counselling Point for Families
It is important to counsel premutation carrier mothers that the risk of CGG expansion to full mutation in offspring depends on the size of the maternal premutation. A mother with 60 CGG repeats has a ~5% risk of having a child with a full mutation, whereas a mother with 100+ repeats has > 90% risk. This information is crucial for reproductive decision-making.
Chromosome analysis showing a classical "fragile site" in the distal part of Xq (a visible gap or constriction at Xq27.3 due to local failure of chromatin condensation) was historically used to identify FXS [1]. This required culturing lymphocytes in folate-depleted or thymidine-stressed medium. However, this method is:
- Insensitive (does not detect all carriers)
- Non-specific (other fragile sites exist on the X chromosome)
- Cannot distinguish premutation from full mutation
- No longer used for clinical diagnosis — entirely replaced by molecular testing
| Step | Action | Key Point |
|---|---|---|
| 1 | Clinical suspicion | Child with GDD/ID/ASD/characteristic features/family history |
| 2 | Order FMR1 CGG repeat analysis | Gold standard; NOT karyotype, NOT CMA [1][2][3] |
| 3 | PCR ± Southern blot | PCR for screening; Southern blot for sizing large expansions and methylation status |
| 4 | Interpret CGG repeat number | Normal ( < 45), intermediate (45–54), premutation (55–200), full mutation ( > 200) |
| 5 | Confirm methylation | Full mutation + methylation = gene silenced = FXS confirmed |
| 6 | Post-diagnosis workup | Developmental assessment, echo, ophthalmology, audiology, ASD/ADHD screening |
| 7 | Cascade family testing + genetic counselling | Mandatory — identify at-risk maternal relatives [3] |
| 8 | Reproductive counselling | CVS/amniocentesis/PGT-M options for future pregnancies |
High Yield Summary – Diagnosis of FXS
- FXS is diagnosed by molecular testing (FMR1 CGG repeat analysis), NOT by karyotype or CMA [3]
- Karyotype is NORMAL in FXS (46,XY or 46,XX) [3]
- Two-step molecular approach: PCR (screening) → Southern blot (confirmation of full mutation + methylation)
- Full mutation = > 200 CGG repeats + hypermethylation → FMR1 silenced → absent FMRP
- Premutation = 55–200 repeats → gene ACTIVE → RNA toxicity (not classic FXS but risk of FXTAS/FXPOI)
- Test any child with unexplained GDD, ID, or ASD for FXS
- Cascade testing of maternal relatives is mandatory after diagnosis
- Post-diagnosis: developmental assessment, echo for MVP, ophthalmology, audiology, seizure monitoring
Active Recall - Diagnosis of Fragile X Syndrome
References
[1] Senior notes: Adrian Lui Pediatrics Notes.pdf (p. 497) [2] Senior notes: MBBS Final MB (Pediatrics) (Felix PY Lai).pdf (pp. 880, 882–883) [3] GC Lecture slides: GC 151. The malformed child hereditary syndromes and anomalies.pdf (p. 26) [5] Senior notes: Adrian Lui Pediatrics Notes.pdf (p. 86) [7] Senior notes: Ryan Ho Neurology.pdf (p. 102) [9] Senior notes: Maksim Paediatric Notes.pdf (p. 207)
Management of Fragile X Syndrome
There is no cure for Fragile X syndrome. There is no drug that restores FMRP production or reverses the methylation silencing of the FMR1 gene. Management is therefore supportive, symptomatic, and multidisciplinary, centred on:
- Early diagnosis → early intervention (the single most impactful step) [2]
- Optimising developmental potential through therapies and educational support
- Managing co-morbid behavioural and medical conditions (ADHD, anxiety, ASD, seizures, cardiac, orthopaedic)
- Family-centred care: genetic counselling, cascade testing, reproductive planning, psychosocial support
- Surveillance for age-dependent complications (MVP, macro-orchidism, seizures)
GC / Senior Notes – Key Management Principle
"Important to make the diagnosis of FXS early so that appropriate interventions (speech and language therapy, special education support, genetic counselling) can be initiated" [2]. This is the core exam-relevant management statement — early identification enables early intervention, which improves long-term cognitive, behavioural, and adaptive outcomes.
9C. Non-Pharmacological Management (Cornerstone of Treatment)
Non-pharmacological interventions are the mainstay of FXS management. Medications play a supporting role for specific co-morbidities, but therapies and educational support are what most directly improve functional outcomes.
| Therapy | Target | Rationale | Paediatric Considerations |
|---|---|---|---|
| Speech and Language Therapy (SLT) [2] | Expressive and receptive language, pragmatic communication, cluttered speech | Language delay is often the earliest and most significant developmental concern in FXS; FMRP is critical for language network development. SLT addresses articulation, vocabulary, narrative skills, and conversational pragmatics | Begin as soon as delay is identified (often by 18–24 months). Use visual supports, sign language augmentation, and structured language programmes. Address cluttered speech pattern (rapid, irregular rate) specifically |
| Occupational Therapy (OT) | Fine motor skills, sensory processing, self-care skills, handwriting | Sensory hypersensitivity (tactile defensiveness, hyperacusis) is a core feature due to excessive mGluR5 signalling; OT provides sensory integration therapy. Fine motor difficulties relate to hypotonia + joint laxity | Sensory diets (scheduled sensory input to modulate arousal), weighted vests, fidget tools. Adaptive equipment for feeding, dressing. Joint protection strategies for hypermobile joints |
| Physiotherapy (PT) | Gross motor development, hypotonia, balance, coordination | Hypotonia in infancy → delayed motor milestones. Joint laxity → instability. Cerebellar involvement → coordination difficulties | Core strengthening, balance training, gait assessment. Monitor for flat feet (orthotics may be needed). Scoliosis screening at each visit |
| Special Education / Individualised Education Programme (IEP) [2] | Academic learning, executive function, adaptive skills | IQ 20–80 (mean ~50) in males [1]; learning disabilities across all domains but particularly in quantitative/mathematical reasoning. Need structured, small-group or 1:1 instruction with visual learning strategies | Place in appropriate educational setting (mainstream with support vs. special school). Regular reassessment of cognitive level and adaptive skills. In Hong Kong: apply for special educational needs (SEN) support through Education Bureau |
| Behavioural Therapy | Challenging behaviours, anxiety, social skills | Anxiety (social anxiety, generalised), gaze aversion, hand-flapping, self-injurious behaviours. These arise from amygdala hyperreactivity and sensory processing dysfunction | Applied Behaviour Analysis (ABA) for structured skill-building. Cognitive Behavioural Therapy (CBT) adapted for developmental level (for anxiety). Social skills groups. Consistent routines and visual schedules reduce anxiety. Avoid sensory overstimulation in the environment |
Why Early Intervention Matters in FXS
The brain has maximal neuroplasticity in the first 3–5 years of life. Although FMRP is absent, the remaining synaptic machinery can be partially compensated by intensive, structured environmental input during this critical window. Children with FXS who receive early intervention show better language outcomes, improved adaptive behaviour, and reduced severity of behavioural difficulties compared to those diagnosed late. This is why the emphasis in senior notes is on making an early diagnosis [2].
| Intervention | Detail |
|---|---|
| Parent training and education | Teach parents about FXS, expected developmental trajectory, behavioural management strategies, sensory needs. Reduce parental guilt (especially in carrier mothers). Connect to parent support groups (e.g., National Fragile X Foundation, Hong Kong Society for the Rehabilitation of the Disabled) |
| Sibling support | Siblings may experience emotional difficulties (worry, jealousy, embarrassment). Age-appropriate information and support groups |
| Respite care | Caring for a child with moderate-severe ID is exhausting. Arrange respite services to prevent carer burnout |
| Genetic counselling [2][3] | Explain inheritance, recurrence risk, implications for maternal relatives (FXPOI, FXTAS risk). Offer prenatal/PGT-M options. See cascade testing below |
| Transition planning | From adolescence, plan for adult services, vocational training, supported living/employment, guardianship/legal capacity issues |
9D. Pharmacological Management (Symptom-Targeted)
There is no FXS-specific approved drug. All medications used are prescribed off-label for specific co-morbid symptoms. The principle is to treat the symptom (ADHD, anxiety, seizures, etc.) using the same medications as in the general paediatric population, with awareness of FXS-specific considerations.
| Medication | Class | Mechanism | Dose / Notes in Paediatrics | FXS-Specific Considerations |
|---|---|---|---|---|
| Methylphenidate | Stimulant | Blocks dopamine and noradrenaline reuptake → increases prefrontal cortex catecholamines → improves attention and impulse control | Start low (e.g., 5 mg immediate-release in AM for school-age child), titrate to effect. Extended-release formulations (e.g., Concerta, Ritalin LA) preferred for school-day coverage | First-line for ADHD in FXS (as in general paediatric ADHD). May cause appetite suppression, insomnia, irritability. Monitor growth (height/weight) at each visit. Some children with FXS tolerate stimulants less well due to comorbid anxiety — if anxiety worsens, consider switching |
| Dexamphetamine / Lisdexamfetamine | Stimulant | Similar to methylphenidate; releases dopamine + noradrenaline | Second-line stimulant if methylphenidate ineffective or not tolerated | Same considerations as methylphenidate |
| Atomoxetine | Non-stimulant (selective NRI) | Selectively inhibits noradrenaline reuptake in prefrontal cortex | 0.5 mg/kg/day initially, increase over 2–4 weeks to 1.2 mg/kg/day (max ~1.4 mg/kg/day or 100 mg). Takes 4–6 weeks for full effect | Useful when stimulants worsen anxiety (common in FXS). No abuse potential. Less effective for hyperactivity than stimulants but better for anxiety/inattention overlap |
| Guanfacine extended-release | Alpha-2 adrenergic agonist | Stimulates post-synaptic alpha-2A receptors in prefrontal cortex → enhances attention; also dampens sympathetic overactivity → reduces hyperarousal | 1 mg at bedtime, titrate up by 1 mg weekly (max 4 mg/day in children ≥ 6 years) | Particularly useful in FXS because it addresses both ADHD and hyperarousal/anxiety simultaneously. Sedation can be a benefit (helps with sleep disturbance) or a side effect. Monitor BP and HR |
| Clonidine | Alpha-2 adrenergic agonist | Similar to guanfacine but shorter-acting, less selective | 25–50 mcg at bedtime, titrate slowly. Available as transdermal patch | Often used as adjunct to stimulants, or for sleep initiation difficulties. More sedating than guanfacine |
ADHD Treatment Hierarchy in FXS
- First-line: Methylphenidate (most evidence in FXS)
- If anxiety worsens on stimulants: Switch to atomoxetine or guanfacine ER
- Adjuncts for hyperarousal/sleep: Guanfacine or clonidine
- Combination: Stimulant + alpha-2 agonist if needed
Note: Children with FXS under age 5 may respond less well to stimulants than the general ADHD population. Behavioural strategies should always be the first step, with medication added if insufficient.
| Medication | Class | Mechanism | Paediatric Dosing | Notes for FXS |
|---|---|---|---|---|
| Sertraline | SSRI | Inhibits serotonin reuptake → increases serotonergic tone in limbic circuits → reduces anxiety | Start 12.5–25 mg daily (liquid formulation available for young children), titrate to 50–200 mg/day over weeks | First-line pharmacotherapy for anxiety in FXS. FMRP normally modulates serotonin pathways; SSRIs partially compensate. Also helps with repetitive behaviours/OCD-like symptoms |
| Fluoxetine | SSRI | Same mechanism | Start 5–10 mg daily, titrate to 20–60 mg/day | Alternative SSRI; longer half-life (advantage if doses missed). Monitor for activation/behavioural disinhibition in young children |
| Escitalopram | SSRI | Most selective serotonin reuptake inhibitor | Start 5 mg daily, titrate to 10–20 mg/day (approved ≥ 12 years for GAD in many jurisdictions) | Well-tolerated; limited paediatric data under 12 |
Non-pharmacological approaches for anxiety should always be first-line:
- Environmental modification (reduce sensory overload, structured routines, predictable transitions)
- Adapted CBT (using visual and concrete strategies appropriate to cognitive level)
- Relaxation techniques, deep pressure input
SSRI Precautions in Paediatrics
All SSRIs carry an FDA/MHRA black box warning for increased risk of suicidal ideation in children and adolescents (particularly in the first few weeks of treatment). However, in FXS the cognitive level often means this risk is lower and clinical benefit typically outweighs risk. Close monitoring is still mandatory. Start low, go slow, and monitor frequently.
There is no medication that treats ASD core symptoms (social communication deficits). Management is behavioural:
- Applied Behaviour Analysis (ABA)
- Social skills training (adapted to cognitive level)
- PECS (Picture Exchange Communication System) for non-verbal or minimally verbal children
- Structured teaching (TEACCH model)
Medications may be used for associated challenging behaviours (irritability, aggression, self-injury):
| Medication | Class | Indication | Paediatric Dosing | Notes |
|---|---|---|---|---|
| Aripiprazole | Atypical antipsychotic (D2 partial agonist) | Irritability associated with ASD (FDA-approved ≥ 6 years) | Start 2 mg daily, titrate to 5–15 mg/day | Lower risk of metabolic side effects than other atypical antipsychotics. Monitor weight, fasting glucose, lipids, prolactin |
| Risperidone | Atypical antipsychotic (D2/5-HT2A antagonist) | Irritability associated with ASD (FDA-approved ≥ 5 years) | Start 0.25 mg daily (weight < 20 kg) or 0.5 mg daily (weight ≥ 20 kg), titrate slowly (max ~3 mg/day) | More weight gain and prolactin elevation than aripiprazole. Monitor regularly |
Seizures in FXS typically present in childhood and often remit by adolescence [1]. They are usually focal or generalised tonic-clonic, and often respond well to standard anticonvulsants.
| Medication | Indication | Notes for FXS |
|---|---|---|
| Sodium valproate (VPA) | Broad-spectrum AED; useful for generalised seizures | Effective in FXS-related seizures. Caution: weight gain (additive with atypical antipsychotics), teratogenicity (critical counselling for adolescent females — avoid in females of child-bearing potential if possible) |
| Levetiracetam | Broad-spectrum AED | Often preferred in FXS due to favourable side-effect profile and no drug interactions. Can rarely cause behavioural side effects (irritability) — monitor closely in a population already prone to behavioural challenges |
| Carbamazepine / Oxcarbazepine | Focal seizures | Effective for focal seizures. Carbamazepine may interact with other medications (CYP3A4 inducer). Oxcarbazepine has fewer interactions |
| Lamotrigine | Broad-spectrum | Good option; may have mood-stabilising benefits. Requires slow titration to avoid Stevens-Johnson syndrome (especially if used with VPA, which inhibits lamotrigine metabolism) |
Key principle: Seizures in FXS are usually benign and self-limiting. Many children can be weaned off AEDs in adolescence after a seizure-free period of 2+ years. Standard paediatric epilepsy management guidelines apply.
| Approach | Detail |
|---|---|
| Sleep hygiene (first-line) | Consistent bedtime routine, dark quiet room, avoid screens before bed, weighted blanket (sensory benefit), reduce caffeine |
| Melatonin | 0.5–5 mg at bedtime (start low). FMRP is involved in circadian gene regulation; melatonin production may be dysregulated. Well-tolerated with minimal side effects. Available as liquid or tablets. Often very effective in FXS |
| Clonidine | 25–50 mcg at bedtime. Useful for sleep-onset difficulty and can also address hyperarousal/ADHD (dual benefit) |
| Target Symptom | First-Line Drug | Second-Line / Adjunct | Key Monitoring |
|---|---|---|---|
| ADHD | Methylphenidate | Atomoxetine, guanfacine ER | Growth (height/weight), BP, HR, appetite, sleep |
| Anxiety | SSRI (sertraline) | Fluoxetine, escitalopram; non-pharm first | Suicidal ideation (black box), activation, GI upset |
| Irritability / Aggression | Aripiprazole | Risperidone | Weight, fasting glucose/lipids, prolactin |
| Seizures | Levetiracetam or VPA | Lamotrigine, carbamazepine | Seizure diary; VPA: LFTs, weight, teratogenicity |
| Sleep | Melatonin | Clonidine | Sedation, BP (clonidine) |
| Age / Stage | Surveillance Action | Rationale |
|---|---|---|
| At diagnosis | Baseline developmental assessment, echo, ophthalmology, audiology, orthopaedic exam | Establish baseline; detect existing complications |
| Annually (childhood) | Developmental/adaptive reassessment, growth parameters, behavioural screen (ADHD, anxiety, ASD), seizure history, orthopaedic check (scoliosis, flat feet) | Track progress; adjust therapies; detect new issues |
| Puberty | Testicular volume (Prader orchidometer), repeat echo for MVP, review AED need if seizures have remitted, anticipate behavioural changes | Macro-orchidism develops post-puberty [1][2]; MVP may become apparent; seizures often remit |
| Adolescence / Transition | Transition planning to adult services, vocational assessment, legal capacity/guardianship, reproductive counselling (for female carriers), review all medications | Prepare for adult life; many paediatric services end at 18 |
Genetic counselling for the maternal family is essential [2][3]. This is a non-negotiable part of management.
| Action | Detail |
|---|---|
| Test the mother | Determine her CGG repeat number and carrier status |
| Test siblings | May be affected (particularly brothers) or carriers (sisters) |
| Test maternal aunts, grandmother, female cousins [3] | They may carry the premutation or full mutation → at risk for: having FXS children, FXPOI, or FXTAS |
| Reproductive counselling | For known carriers: options include CVS, amniocentesis, PGT-M, donor egg/sperm, adoption |
| FXPOI counselling | Female premutation carriers (~20% risk of premature ovarian failure before age 40): consider early fertility assessment and family planning |
| FXTAS counselling | Male premutation carriers (and occasionally females) > 50 years: risk of progressive tremor/ataxia syndrome |
While not yet standard of care, several targeted therapies based on the "mGluR theory of Fragile X" have been investigated. Understanding these demonstrates the translational potential of FXS pathophysiology research:
| Agent | Mechanism | Status |
|---|---|---|
| mGluR5 antagonists (mavoglurant, basimglurant) | Block excessive mGluR5 signalling (normally inhibited by FMRP) → reduce exaggerated LTD → restore synaptic balance | Phase II/III trials showed no significant benefit on primary endpoints in FXS; development halted |
| GABA-B agonists (arbaclofen) | Enhance inhibitory GABAergic tone to counteract excitation-inhibition imbalance | Mixed results in clinical trials; some improvement in social avoidance subscale but primary endpoints not met |
| Cannabidiol (CBD) | Multiple mechanisms including modulation of endocannabinoid system, anti-anxiety | Anecdotal reports of behavioural improvement; ongoing trials |
| FMR1 gene reactivation (CRISPR-based demethylation, small molecules like 5-azacytidine) | Remove methylation from FMR1 promoter → re-express FMRP | Preclinical/experimental only; potential toxicity concerns with demethylating agents |
| Metformin | Normalises ERK and mTOR signalling pathways (downstream of mGluR5) | Open-label studies showed improvements in behaviour and language in some children with FXS; randomised controlled trials ongoing |
Why Did mGluR5 Antagonists Fail?
The "mGluR theory" was elegant — FMRP normally brakes mGluR5-driven protein synthesis; without FMRP, there is excessive mGluR5 signalling → blocking mGluR5 should restore balance. This worked beautifully in animal models (Fmr1 knockout mice). However, human trials failed, likely because: (1) chronic mGluR5 blockade may have compensatory effects, (2) outcome measures in trials were insensitive, (3) the human FXS phenotype involves more than just mGluR5 dysregulation, and (4) treatment may need to start much earlier (in infancy) before irreversible synaptic damage occurs. This remains an active area of research.
| Medication | Contraindication / Caution | Why |
|---|---|---|
| Stimulants (methylphenidate) | Relative caution if severe anxiety or tics | Stimulants can exacerbate anxiety (common in FXS) and tics. If this occurs, switch to non-stimulant (atomoxetine or guanfacine) |
| SSRIs | Caution in children < 6 years (limited evidence); monitor for activation/disinhibition | Younger children with developmental delay may be unable to articulate suicidal ideation → rely on behavioural monitoring |
| Valproate | Avoid in adolescent females of childbearing potential if possible | Teratogenicity (neural tube defects, developmental delay in offspring); use levetiracetam or lamotrigine instead |
| Risperidone / Aripiprazole | Monitor metabolic parameters; caution with prolonged use | Weight gain → obesity (already a risk in FXS due to reduced physical activity); metabolic syndrome; prolactin elevation (risperidone > aripiprazole) |
| Clonidine | Avoid abrupt withdrawal | Rebound hypertension; taper gradually |
| Carbamazepine | Drug interactions (potent CYP inducer) | Can reduce levels of co-administered medications; check for HLA-B*1502 in Han Chinese population (risk of SJS/TEN) |
High Yield Summary – Management of FXS
- No cure exists; management is supportive, symptomatic, and multidisciplinary
- Early diagnosis → early intervention is the single most important step [2]
- Core therapies: speech-language therapy, OT, physiotherapy, special education (IEP) [2]
- Pharmacotherapy is symptom-targeted (not FXS-specific):
- ADHD → methylphenidate first-line; guanfacine if anxiety co-exists
- Anxiety → SSRI (sertraline); behavioural/environmental strategies first
- Irritability/aggression → aripiprazole or risperidone
- Seizures → levetiracetam or valproate; often remit by adolescence
- Sleep → melatonin; clonidine as adjunct
- Genetic counselling and cascade testing of maternal relatives is mandatory [2][3]
- Medical surveillance: echo for MVP, ophthalmology, audiology, scoliosis screening, pubertal monitoring for macro-orchidism
- Transition planning for adolescents to adult services is essential
- mGluR5 antagonists failed in clinical trials despite strong preclinical rationale; metformin is under investigation
Active Recall - Management of Fragile X Syndrome
References
[1] Senior notes: Adrian Lui Pediatrics Notes.pdf (p. 497) [2] Senior notes: MBBS Final MB (Pediatrics) (Felix PY Lai).pdf (pp. 882–883) [3] GC Lecture slides: GC 151. The malformed child hereditary syndromes and anomalies.pdf (p. 26)
Complications of Fragile X Syndrome
The complications of FXS stem directly from the absence of FMRP and its downstream effects on multiple organ systems. FMRP is not just a "brain protein" — it is expressed broadly, including in neurons, connective tissue, cardiac valves, testes, and the retina. Therefore, complications span neurodevelopmental, behavioural/psychiatric, cardiac, musculoskeletal, and reproductive domains.
It is also important to distinguish between:
- Complications intrinsic to FXS (direct consequences of absent FMRP)
- Complications of the premutation state (RNA toxicity — a different mechanism, affecting different individuals)
- Iatrogenic complications (side effects of medications used to manage FXS symptoms)
10B. Neurodevelopmental and Cognitive Complications
| Feature | Detail | Pathophysiological Basis |
|---|---|---|
| Moderate-to-severe ID in males (IQ 20–80, mean ~50) [1][9] | The defining complication of FXS. Affects learning, adaptive function, independence, vocational capacity, and quality of life | Absent FMRP → unregulated synaptic protein synthesis → immature dendritic spines → impaired synaptic plasticity and learning circuits |
| Mild-to-moderate ID in ~40–50% of females with full mutation [1] | Variable due to X-inactivation; some females have normal IQ but still have executive function difficulties | Random lyonisation: favourable X-inactivation ratio → more normal X active → more FMRP → milder phenotype |
| Cognitive decline (apparent, not true regression) | Cognitive level and adaptive behaviour skills decline after early childhood, reflecting the slow acquisition of skills compared with other children of the same age rather than a regression of skills [2] | Skills are acquired more slowly than peers → widening gap over time → apparent "decline" in standardised scores. This is NOT neurodegeneration |
Important Distinction – Apparent Decline vs. True Regression
Parents and clinicians may perceive a "decline" in IQ scores over childhood. This is an artefact of standardised testing: as the child ages, peers acquire skills faster, so the FXS child's relative score drops even though they are still learning new things. True regression (loss of previously acquired skills) does NOT occur in FXS [2]. If genuine regression occurs, investigate for another diagnosis (Rett syndrome, metabolic disorder, epileptic encephalopathy).
| Complication | Detail | Mechanism |
|---|---|---|
| Delayed language development | Expressive language skills achieved more slowly than receptive language skills [2] | FMRP regulates mRNA for synaptic proteins in Broca's area (expressive language) and broader language networks; expressive circuits may be more vulnerable |
| Characteristic speech cluttering | Rapid, irregular rate makes speech difficult to understand [2] | Motor speech planning dysfunction + executive function impairment (difficulty regulating speech output rate) |
| Perseverative / repetitive speech | Echolalia, repetitive phrases, tangential conversation | Frontal lobe executive dysfunction → inability to inhibit verbal output |
| Feature | Detail |
|---|---|
| Prevalence in FXS | ~30% of males with FXS meet DSM-5 criteria for ASD; ~20% meet broader ASD criteria without full diagnosis [5][6][14] |
| Features | Social anxiety with gaze aversion (but often socially interested — distinct from "classic" ASD), hand flapping, stereotypic movements, sensory hypersensitivity, difficulty with social reciprocity |
| Impact | ASD co-morbidity is associated with lower cognitive outcomes, more challenging behaviours, and greater need for intensive support |
GC Lecture Slide – High Yield
GC 151 [14] lists Fragile X syndrome as one of several rare diseases found among common diseases — specifically naming FXS alongside isodicentric chromosome 15, distal 16p11.2 deletion, PTEN mutation, and Phelan-McDermid syndrome (SHANK3/22q13 deletion) as genetic causes identified within ASD cohorts. This reinforces that FXS should always be considered in the genetic workup of ASD [14].
| Feature | Detail |
|---|---|
| Prevalence | ~80% of males with FXS have clinically significant ADHD symptoms |
| Subtype | Combined type (inattention + hyperactivity-impulsivity) most common |
| Complication | ADHD significantly impairs educational attainment and social functioning beyond what ID alone causes; adds to behavioural management challenges |
| Complication | Prevalence | Mechanism | Impact |
|---|---|---|---|
| Anxiety disorders (social anxiety, generalised anxiety, selective mutism) | ~70–80% of males | Amygdala hyperreactivity due to absent FMRP modulation of fear circuits; sensory overload → hyperarousal | Social avoidance, school refusal, difficulty in group settings, self-injurious behaviour when overwhelmed |
| Sensory hypersensitivity (hyperacusis, tactile defensiveness) | Very common | Excessive mGluR5-driven excitatory signalling → lowered sensory threshold | Environmental adaptations required; contributes to meltdowns and avoidance behaviours |
| Aggression / Self-injurious behaviour (SIB) | ~30–50% | Frustration from communication difficulty + sensory overload + anxiety → behavioural dysregulation | Hand-biting (characteristic), head-banging, hitting. May require behavioural intervention ± pharmacotherapy |
| Mood disorders | Less well-characterised in children; depression can emerge in adolescence | Serotonergic dysfunction (FMRP modulates serotonin receptor mRNA) | Screen for depression in adolescents, especially those with insight into their differences |
| Sleep disturbance | ~30–50% | Dysregulated melatonin production (FMRP involved in circadian gene expression) | Impacts daytime behaviour, learning, family functioning; often responds to melatonin |
| Complication | Prevalence | Mechanism | Clinical Significance |
|---|---|---|---|
| Mitral valve prolapse (MVP) [1][2] | ~50% of adults with FXS; less common in childhood | FMRP regulates extracellular matrix proteins (elastin, collagen) → connective tissue dysplasia → myxomatous degeneration of mitral valve leaflets (similar to Marfan syndrome) | Usually benign — mid-systolic click ± late systolic murmur on auscultation. Majority have no significant mitral regurgitation (MR). Echo surveillance recommended. If significant MR develops → volume overload → LV dilatation → heart failure (rare in paediatric FXS) |
| Mitral regurgitation (MR) | Subset of those with MVP | MVP → leaflet malcoaptation → regurgitant jet during systole | If moderate-severe MR: endocarditis prophylaxis in specific dental/surgical procedures (per current guidelines); cardiology follow-up. Surgical intervention (valve repair/replacement) is exceedingly rare in FXS |
| Aortic root dilatation | Rare | Connective tissue dysplasia affecting aortic wall (similar mechanism to MVP) | Much less common than in Marfan syndrome. Echo screening at baseline; repeat if abnormal |
MVP in FXS – Usually Benign But Requires Monitoring
Unlike Marfan syndrome where aortic complications are life-threatening, the cardiac complications of FXS are generally mild and well-tolerated. Most children with FXS and MVP are asymptomatic. However, baseline echocardiography at diagnosis is recommended, with repeat in adolescence/adulthood, to detect the minority who develop significant MR [1][2].
| Complication | Prevalence | Mechanism | Management |
|---|---|---|---|
| Joint hypermobility [1][2] | Very common (> 50%) | FMRP regulates elastin/collagen gene expression → reduced structural integrity of ligaments and joint capsules | May cause joint instability, recurrent subluxations (especially fingers, patella), pain during physical activity. Physiotherapy for joint strengthening; avoid high-impact sports that stress hypermobile joints |
| Pes planus (flat feet) | Very common | Ligamentous laxity of foot arches | Custom orthotics/arch supports; supportive footwear; physiotherapy for intrinsic foot muscles |
| Scoliosis [1] | ~20% of affected individuals | Hypotonia + connective tissue laxity → vertebral malalignment; may worsen during growth spurts | Regular spinal screening (Adams forward bend test) at each visit; referral to orthopaedics if curve > 10°; bracing for moderate curves; surgery rarely needed |
| Recurrent otitis media | Common in childhood | Eustachian tube dysfunction (likely related to connective tissue laxity of tubal cartilage + hypotonia of tensor veli palatini) → poor middle ear ventilation → recurrent infection | May cause conductive hearing loss if chronic → impacts language development (already vulnerable). Aggressive management: antibiotics, grommets (tympanostomy tubes) if recurrent. Audiology screening at diagnosis and regularly |
| Feature | Detail |
|---|---|
| Prevalence | ~10–20% of males with FXS [1] |
| Seizure types | Most commonly benign focal seizures (especially centrotemporal, resembling benign epilepsy with centrotemporal spikes / BECTS) or generalised tonic-clonic seizures |
| Age of onset | Typically childhood (2–10 years) |
| Prognosis | Usually remit by adolescence — many children can be weaned off anticonvulsants after a seizure-free period |
| Complications of seizures | Injury during seizures, cognitive impact if uncontrolled (status epilepticus is rare), drug side effects, impact on school attendance |
| EEG findings | May show centrotemporal spikes (similar to BECTS) or generalised spike-wave discharges |
| Complication | Prevalence | Mechanism | Management |
|---|---|---|---|
| Strabismus [2] | Common (~30–40%) | Impaired coordination of extraocular muscles (related to neurological dysfunction + possible connective tissue factors) | Ophthalmology referral; patching therapy, corrective lenses, or surgical correction if persistent |
| Refractive errors (hypermetropia, myopia, astigmatism) | Common | Altered eye growth and lens development | Regular refraction checks; corrective lenses |
| Nystagmus | Occasional | Central nervous system involvement | Evaluate for underlying cause |
| Complication | Who Is Affected | Mechanism | Notes |
|---|---|---|---|
| Macro-orchidism [1][2] | Post-pubertal males with full mutation (> 80%) | Absent FMRP → unregulated Sertoli cell proliferation → seminiferous tubule enlargement (NOT due to increased testosterone; testicular function is usually normal) | Testicular volume > 25–30 mL (normal adult 15–25 mL). Fertility is usually preserved in males with FXS (unlike Klinefelter syndrome). The concern is cosmetic/psychosocial rather than functional |
| Fragile X-associated Primary Ovarian Insufficiency (FXPOI) | Female premutation carriers (~20%) | RNA toxicity from excess FMR1 mRNA (premutation mechanism, NOT full mutation) → damages ovarian follicles → accelerated follicular depletion | Menopause before age 40. NOT a complication of FXS per se but of the premutation. Important for genetic counselling of carrier mothers/aunts — early fertility assessment is recommended |
| FXTAS | Male (and occasionally female) premutation carriers > 50 years | RNA gain-of-function toxicity → intranuclear inclusions in neurons/astrocytes → progressive cerebellar ataxia, intention tremor, cognitive decline, parkinsonism | NOT a complication of FXS (full mutation) but of the premutation state. Important to counsel families that premutation grandfathers/uncles may develop this progressive neurodegenerative condition |
FXPOI and FXTAS Are Premutation Complications, NOT Full-Mutation Complications
A common exam error is attributing FXPOI and FXTAS to FXS (full mutation). These conditions are caused by the premutation (55–200 repeats) through RNA toxicity (excess FMR1 mRNA), which is a completely different mechanism from the full mutation (gene silencing → absent FMRP). Individuals with the full mutation do NOT develop FXTAS or FXPOI. However, their carrier mothers/maternal relatives (premutation carriers) may be at risk — which is why cascade testing and counselling is essential [1][2][3].
| Complication | Detail |
|---|---|
| Impact on the child | Social isolation (due to anxiety, behavioural challenges, ID), bullying at school, reduced self-esteem (especially in those with mild-moderate ID who have some insight), difficulty forming friendships, limited vocational opportunities in adulthood |
| Impact on parents | Maternal guilt (carrier mothers often feel responsible), chronic stress from caring for a child with moderate-severe ID + behavioural challenges, financial burden (therapies, special education), marital strain, anxiety about recurrence risk in future pregnancies |
| Impact on siblings | Emotional burden ("parentification" of older siblings), worry about their own carrier status, less parental attention, adjustment difficulties |
| Impact on maternal relatives | Learning of premutation carrier status may cause anxiety about own health (FXPOI risk, FXTAS risk) and reproductive implications |
| Treatment | Potential Complication | Monitoring |
|---|---|---|
| Methylphenidate (for ADHD) | Appetite suppression → weight loss/growth deceleration; insomnia; exacerbation of anxiety; tics; rebound irritability | Height/weight at each visit; sleep diary; anxiety screening |
| SSRIs (for anxiety) | Activation/behavioural disinhibition (especially in young children); GI upset; serotonin syndrome (rare, if combined with other serotonergic agents) | Behavioural monitoring in first 4–6 weeks; suicidal ideation monitoring in adolescents |
| Atypical antipsychotics (aripiprazole, risperidone) | Weight gain → metabolic syndrome (obesity, dyslipidaemia, insulin resistance, T2DM); prolactin elevation (risperidone > aripiprazole) → gynaecomastia, galactorrhoea; sedation; extrapyramidal symptoms (rare with atypicals) | Fasting glucose/lipids, weight, BMI, prolactin, waist circumference every 6–12 months |
| Valproate (for seizures) | Teratogenicity (neural tube defects, neurodevelopmental harm in offspring) if used in females of childbearing potential; weight gain; hepatotoxicity (rare, more common < 2 years); thrombocytopenia; pancreatitis (rare) | LFTs, CBP, weight; contraception counselling in adolescent females; consider alternative AED |
| Melatonin (for sleep) | Generally very safe; occasionally daytime drowsiness, vivid dreams, headache | Rarely requires monitoring; assess effectiveness regularly |
| Aspect | Outcome |
|---|---|
| Life expectancy | Normal or near-normal in FXS. Unlike some genetic syndromes (e.g., Down syndrome with major cardiac defects, or storage disorders), FXS does not typically shorten lifespan significantly |
| Independence | Males with moderate-severe ID usually require supported living in adulthood (supervised group homes, day programmes). Some with mild-moderate ID can achieve semi-independent living with support |
| Employment | Most males with FXS require sheltered or supported employment. Females with mild ID may achieve competitive employment with accommodations |
| Relationships | Social anxiety can limit social networks. Some individuals with FXS form meaningful friendships and romantic relationships, particularly those with milder phenotypes |
| Fertility | Males with FXS are usually fertile (macro-orchidism does not impair spermatogenesis). If a male with the full mutation reproduces (rare due to severity of ID), all daughters will be obligate premutation carriers (the full mutation contracts back to premutation during spermatogenesis) |
| System | Complication | Prevalence | Severity |
|---|---|---|---|
| Neurodevelopmental | ID (moderate-severe in males) | ~100% of males with full mutation | Core feature; lifelong |
| Behavioural/Psychiatric | ADHD, anxiety, ASD, aggression, sleep disturbance | 70–80% (ADHD/anxiety); ~30% (ASD) | Variable; manageable with multimodal approach |
| Seizures | Focal/generalised seizures | 10–20% | Usually benign; often remit by adolescence |
| Cardiovascular | MVP ± MR | ~50% of adults | Usually mild and asymptomatic |
| Musculoskeletal | Joint laxity, scoliosis, flat feet | > 50% | Functional impairment possible; rarely severe |
| Ophthalmological | Strabismus, refractive errors | 30–40% | Treatable |
| ENT | Recurrent otitis media, conductive hearing loss | Common in childhood | Can worsen language delay if untreated |
| Genital | Macro-orchidism | > 80% post-pubertal males | Cosmetic concern; fertility usually preserved |
| Premutation-specific | FXPOI, FXTAS | 20% (FXPOI); variable (FXTAS) | Affects premutation carriers, NOT full mutation |
High Yield Summary – Complications of FXS
- ID is the core complication — moderate-severe in males (IQ 20–80, mean ~50), mild-moderate in ~40–50% of females [1]
- Apparent cognitive "decline" is due to slowing of skill acquisition relative to peers, NOT true regression [2]
- ADHD (~80%), anxiety (~70–80%), and ASD (~30%) are the most impactful behavioural co-morbidities
- Seizures (10–20%) are usually benign and remit by adolescence [1]
- MVP (~50% of adults) is usually asymptomatic; echo surveillance recommended [1][2]
- Joint laxity, scoliosis, flat feet — connective tissue complications requiring physiotherapy and monitoring
- Macro-orchidism develops post-puberty; fertility is usually preserved
- Strabismus and recurrent otitis media should be screened for at diagnosis to prevent worsening of language delay
- FXPOI and FXTAS are premutation complications (RNA toxicity), NOT full-mutation complications — important distinction for counselling
- Life expectancy is normal — the main impact is on quality of life, independence, and psychosocial functioning
- Iatrogenic complications from ADHD medications, antipsychotics, and AEDs require regular monitoring
Active Recall - Complications of Fragile X Syndrome
References
[1] Senior notes: Adrian Lui Pediatrics Notes.pdf (p. 497) [2] Senior notes: MBBS Final MB (Pediatrics) (Felix PY Lai).pdf (pp. 880, 882–883) [3] GC Lecture slides: GC 151. The malformed child hereditary syndromes and anomalies.pdf (p. 26) [5] Senior notes: Adrian Lui Pediatrics Notes.pdf (p. 86) [6] Senior notes: Ryan Ho Psychiatry.pdf (pp. 244, 251, 256) [9] Senior notes: Maksim Paediatric Notes.pdf (p. 207) [14] GC Lecture slides: GC 151. The malformed child hereditary syndromes and anomalies.pdf (p. 24)
High Yield Summary
Fragile X Syndrome – Key Points for Exams:
- Most common inherited cause of intellectual disability (distinguish from Down syndrome, which is the most common genetic cause overall)
- X-linked; FMR1 gene at Xq27.3; CGG trinucleotide repeat expansion in the 5' UTR (non-coding region)
- 99% caused by trinucleotide repeat expansion → hypermethylation → absent FMRP
- Repeat ranges: Normal (~5–44), Premutation (55–200), Full mutation ( > 200)
- Full mutation: gene silenced → no FMRP → loss of function
- Premutation: gene overactive → excess mRNA → RNA toxicity (FXTAS, FXPOI)
- Anticipation: repeats expand through generations (especially maternal transmission)
- Sherman Paradox: unaffected male → carrier daughter → affected grandson
- Clinical triad: Intellectual disability + Large ears/long face + Macro-orchidism (after puberty)
- Associated features: ASD (~30%), ADHD, anxiety, joint laxity, MVP, seizures (10–20%)
- Females: 40–50% with full mutation have learning difficulty (variable due to X-inactivation)
- Diagnosis: Molecular analysis of CGG repeat number in FMR1 (NOT standard karyotype)
- Standard karyotype is NORMAL (46,XY) – fragile site only seen under special conditions
- Genetic counselling of maternal relatives is mandatory
High Yield Summary – Diagnosis of FXS
- FXS is diagnosed by molecular testing (FMR1 CGG repeat analysis), NOT by karyotype or CMA [3]
- Karyotype is NORMAL in FXS (46,XY or 46,XX) [3]
- Two-step molecular approach: PCR (screening) → Southern blot (confirmation of full mutation + methylation)
- Full mutation = > 200 CGG repeats + hypermethylation → FMR1 silenced → absent FMRP
- Premutation = 55–200 repeats → gene ACTIVE → RNA toxicity (not classic FXS but risk of FXTAS/FXPOI)
- Test any child with unexplained GDD, ID, or ASD for FXS
- Cascade testing of maternal relatives is mandatory after diagnosis
- Post-diagnosis: developmental assessment, echo for MVP, ophthalmology, audiology, seizure monitoring
High Yield Summary – Management of FXS
- No cure exists; management is supportive, symptomatic, and multidisciplinary
- Early diagnosis → early intervention is the single most important step [2]
- Core therapies: speech-language therapy, OT, physiotherapy, special education (IEP) [2]
- Pharmacotherapy is symptom-targeted (not FXS-specific):
- ADHD → methylphenidate first-line; guanfacine if anxiety co-exists
- Anxiety → SSRI (sertraline); behavioural/environmental strategies first
- Irritability/aggression → aripiprazole or risperidone
- Seizures → levetiracetam or valproate; often remit by adolescence
- Sleep → melatonin; clonidine as adjunct
- Genetic counselling and cascade testing of maternal relatives is mandatory [2][3]
- Medical surveillance: echo for MVP, ophthalmology, audiology, scoliosis screening, pubertal monitoring for macro-orchidism
- Transition planning for adolescents to adult services is essential
- mGluR5 antagonists failed in clinical trials despite strong preclinical rationale; metformin is under investigation
High Yield Summary – Complications of FXS
- ID is the core complication — moderate-severe in males (IQ 20–80, mean ~50), mild-moderate in ~40–50% of females [1]
- Apparent cognitive "decline" is due to slowing of skill acquisition relative to peers, NOT true regression [2]
- ADHD (~80%), anxiety (~70–80%), and ASD (~30%) are the most impactful behavioural co-morbidities
- Seizures (10–20%) are usually benign and remit by adolescence [1]
- MVP (~50% of adults) is usually asymptomatic; echo surveillance recommended [1][2]
- Joint laxity, scoliosis, flat feet — connective tissue complications requiring physiotherapy and monitoring
- Macro-orchidism develops post-puberty; fertility is usually preserved
- Strabismus and recurrent otitis media should be screened for at diagnosis to prevent worsening of language delay
- FXPOI and FXTAS are premutation complications (RNA toxicity), NOT full-mutation complications — important distinction for counselling
- Life expectancy is normal — the main impact is on quality of life, independence, and psychosocial functioning
- Iatrogenic complications from ADHD medications, antipsychotics, and AEDs require regular monitoring
Beckwith-wiedemann Syndrome
Beckwith-Wiedemann syndrome is a congenital overgrowth disorder, typically presenting at birth or in early childhood, characterized by macrosomia, macroglossia, omphalocele, visceromegaly, and an increased risk of embryonal tumors such as Wilms tumor and hepatoblastoma.
Friedreich Ataxia
Friedreich ataxia is an autosomal recessive neurodegenerative disorder, typically presenting in childhood or adolescence (usually before age 25), caused by GAA trinucleotide repeat expansions in the frataxin gene, leading to progressive gait and limb ataxia, dysarthria, loss of deep tendon reflexes, and hypertrophic cardiomyopathy.